Vectura is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases worldwide.

Vectura Group plc and Skyepharma PLC merger completed on 10 June 2016

Vectura Group plc All Share Merger with Skyepharma PLC

   Investors

Date: 09/12/2016

Share price summary

At a glance

INHALED PRODUCT DEVELOPMENT

(Partnered and wholly owned)

Supported by Clinical and Regulatory teams, Quality and IP

DEVICE DESIGN AND DEVELOPMENT

(DPIs, pMDIs and smart nebulisers)

Making Vectura the partner of choice in airways diseases with a range of DPIs, pMDIs and smart nebuliser devices for inhaled delivery of drugs to the lungs

FORMULATION

(Development services)

Pharmaceutical development services
(fee-for-service activities for partners)

DEVICE MANUFACTURING AND COMMERCIALISATION

(DPIs, pMDIs and smart nebulisers)

Underpinning our product development focus through stages of pre-clinical and clinical development ensuring successful commercialisation in partner’s or contract manufacturing facilities

ORAL DRUG DEVELOPMENT

(Oral drug delivery solutions and technologies)

Capabilities include formulation, scale-up, regulatory affairs and commercial manufacture

Established in 1997 with head office in Chippenham, Wiltshire, UK

On-site product and formulation development and manufacturing capability